-- For families living with familial adenomatous polyposis (FAP), research into new treatment options is especially important. FAP is a rare inherited condition that causes hundreds or even thousands of polyps to form in the colon and rectum. Without treatment, these polyps have a very high risk of developing into colorectal cancer.
For many people living with FAP, management involves regular monitoring and major surgery, often including removal of part or all of the colon.
The Phase 3 Serenta Trial is investigating a potential non-surgical treatment for FAP and has now reached an important milestone: 50% of the study’s planned participants have been enrolled.
The trial remains open to recruitment at participating study sites.
Learn more about the study and qualification at serentatrial.com.
An Important Milestone for the Serenta Trial
Reaching 50% recruitment marks significant progress for the Serenta Trial and for the researchers, clinical teams and families involved in the study.
Clinical trials depend on participation from people who meet carefully defined eligibility criteria. Reaching the halfway point means that a substantial number of participants are now contributing to research aimed at understanding whether a new treatment approach could benefit people living with FAP.
The milestone relates to recruitment progress only. The trial is still ongoing, and no conclusions can yet be drawn about the effectiveness of the treatment being studied.
Additional eligible participants are still needed before recruitment can be completed.
What Is the Serenta Trial?
The Serenta Trial is a Phase 3 clinical trial testing a drug called eRapa in people with familial adenomatous polyposis.
Unlike surgery, eRapa is taken as a capsule. It is being studied to determine whether it can help slow or reduce the development of polyps associated with FAP.
Earlier clinical research produced promising findings, leading researchers to progress to the current Phase 3 study.
The Serenta Trial is being conducted across multiple clinical trial sites in the United States, Canada and Europe, allowing people with FAP from different regions to contribute to the research.
Why Research Into FAP Matters
FAP is caused by an inherited genetic change and often affects several members of the same family across generations.
Without effective management, the risk of colorectal cancer is extremely high. Surgery has therefore played a central role in reducing that risk, but major gastrointestinal surgery can also have lifelong effects on health and quality of life.
Research into potential medical treatments could provide another way of managing the condition in the future.
The purpose of the Serenta Trial is to establish whether eRapa can provide a safe and effective treatment option for people with FAP.
Who May Be Eligible?
The Serenta Trial is seeking participants with confirmed familial adenomatous polyposis who meet the study’s eligibility criteria.
Clinical trial eligibility depends on several factors, including medical history and the specific requirements of the study. A clinical trial team can assess whether participation may be appropriate.
Participation may involve:
- Taking the study drug or a placebo capsule.
- Attending scheduled study visits and assessments.
- Regular monitoring by the clinical trial team.
- Contributing information that helps researchers understand the potential benefits and risks of the treatment.
Participation in any clinical trial is voluntary, and deciding whether to join a study is a personal decision that can be discussed with medical professionals and the trial team.
Continuing Toward Full Recruitment
The 50% recruitment milestone represents an important step, but the Serenta Trial still needs additional eligible participants to complete the study.
Every participant contributes to the evidence researchers need to determine whether a potential new treatment is effective and safe.
For families affected by a rare inherited condition such as FAP, clinical research also contributes to a broader understanding of the condition and the treatment options that may be available to future generations.
How to Learn More
Information about the Serenta Trial is available at serentatrial.com, including:
- Details about the Phase 3 clinical trial.
- Information about who may qualify.
- Participating clinical trial locations.
- Information about what taking part involves.
The Serenta Trial reaching 50% recruitment is an encouraging sign of progress in an important area of FAP research. With recruitment continuing, the study is moving closer to the point at which researchers can fully evaluate this potential new approach to treating familial adenomatous polyposis.
More information about the study and current participating sites can be found at serentatrial.com.
Contact Info:
Name: Kate Bamsey
Email: Send Email
Organization: Serenta Trial
Website: https://serentatrial.com/
Release ID: 89201238
In the event of any inaccuracies, problems, or queries arising from the content shared in this press release, we encourage you to notify us immediately at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our diligent team will be readily available to respond and take swift action within 8 hours to rectify any identified issues or assist with removal requests. Ensuring the provision of high-quality and precise information is paramount to us.
